Dear Shareholder

On behalf of the Board of AstraZeneca PLC (the Company), I am pleased to confirm that the Annual Report and Form 20-F Information 2016 (the Annual Report) has now been published, as well as the Notice of Annual General Meeting 2017 and Shareholders’ Circular (the Notice of AGM).

What you should have received
If you have previously requested paper copies of these documents, you will find paper copies enclosed.

If you have previously elected to receive these documents via the AstraZeneca website, you can now access the Annual Report at www.astrazeneca.com/annualreport2016 and the Notice of AGM at www.astrazeneca.com/noticeofmeeting2017.

Everyone who receives a hard copy of this document will also find enclosed a proxy card.

An ‘at a glance’ summary of the Company’s performance during 2016 is included on pages 2 and 3 of this document. Useful information for shareholders is set out on page 4.

Communicating with you
I would urge shareholders who receive communications from the Company in hard copy to consider opting to receive all future information from the Company in electronic format. There are clear environmental benefits and cost savings arising from reduced paper usage, printing and distribution if you do so.

You can elect to receive shareholder communications in electronic format by registering your details at www.shareview.co.uk and electing for e-communications. Whenever shareholder communications are published, we will send you an email with a link to the information on the AstraZeneca website. Please note that dividend notifications will continue to be sent to all shareholders by post.

Yours faithfully

Leif Johansson
Chairman
16 March 2017

Important information
This document contains certain statements extracted from the Annual Report and Form 20-F Information 2016 (Annual Report) for AstraZeneca PLC that are neither reported financial results nor other historical information. These statements are forward-looking statements, including within the meaning of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those disclosed in our forward-looking statements. For a description of factors that could affect future results, reference should be made to the full ‘Cautionary statement’ on page 243 of the Annual Report and to the section entitled ‘Risk’ on pages 214 to 225. This information is provided solely for the convenience of current and future members of the Company and is not intended to satisfy any statutory and/or regulatory requirements in the UK or elsewhere. Accordingly, it should only be read in conjunction with the Annual Report. The Company, its subsidiaries, Directors and officers shall not be liable for the consequence of any action taken solely in reliance on the information contained in this document.
AstraZeneca at a glance

A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines:

1. Achieve scientific leadership
2. Return to growth
3. Be a great place to work

A science-led, innovation strategy
Distinctive R&D capabilities: small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science

<table>
<thead>
<tr>
<th>12 new molecular entities (NMEs) in Phase III/pivotal Phase II or under regulatory review</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
</tr>
<tr>
<td>2015</td>
</tr>
<tr>
<td>2014</td>
</tr>
<tr>
<td>2013</td>
</tr>
</tbody>
</table>

Broad R&D platform in three main therapy areas

**Oncology**
- Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations. We seek to achieve this by means of our combination-focused pipeline that exploits the power of four scientific platforms

**Cardiovascular & Metabolic Disease**
- We push the boundaries of science to create life-changing medicines for patients that reduce morbidity, mortality and organ damage by addressing multiple risk factors

**Respiratory**
- We aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologic medicines along with scientific research targeting disease modification

Portfolio of specialty and primary care products

**Oncology**
- $3,383m
  - Product Sales
    - 2015: $2,825m
    - 2014: $3,027m
- Lynparza (sales of $218 million) available in 31 countries by end 2016
- Iressa sales of $513 million, down 6% (5% at CER), as we prioritised Tagrisso

**Cardiovascular & Metabolic Disease**
- $8,116m
  - Product Sales
    - 2015: $9,489m
    - 2014: $9,802m
- Onglyza sales in the US declined 10% to $376 million, as we prioritised Farxiga
- In the US, Crestor sales declined 57% to $1,223 million, reflecting entry of generic Crestor

**Respiratory**
- $4,753m
  - Product Sales
    - 2015: $4,987m
    - 2014: $5,063m
- Pulmicort sales of $1,061 million, up 5% (8% at CER)
- Bevespi Aerosphere inhalation aerosol launched in the US in January 2017

**Other Disease Areas**
- $5,067m
  - Product Sales
    - 2015: $6,340m
    - 2014: $8,203m
- Nexium sales of $2,032 million, down 29% (30% at CER) and Seroquel XR sales of $735 million, down 1% (2% at CER) following loss of exclusivity
Global commercial presence, with strength in Emerging Markets

<table>
<thead>
<tr>
<th>US</th>
<th>Europe</th>
<th>Established Rest of World</th>
<th>Emerging Markets</th>
</tr>
</thead>
<tbody>
<tr>
<td>$7,365m</td>
<td>$5,064m</td>
<td>$3,096m</td>
<td>$5,794m</td>
</tr>
</tbody>
</table>

Product Sales

- **US**: 2015: $9,474m, 2014: $10,120m
- **Europe**: 2015: $5,323m, 2014: $6,638m
- **Established Rest of World**: 2015: $3,022m, 2014: $3,510m
- **Emerging Markets**: 2015: $5,822m, 2014: $5,827m

Commercial Highlights: Growth Platforms grew by 4% (5% at CER) in 2016

- Emerging Markets: Stable (growth of 6% at CER), supported by China, up 4% (10% at CER) to $2,636 million
- Diabetes: Growth of 9% (11% at CER), as Farxiga/Forxiga became our largest-selling Diabetes medicine
- Japan: Sales up 8% (decline of 3% at CER), reflecting exchange rate impact and a biennial price reduction
- Brilinta/Brilique sales grew by 36% (39% at CER)
- Respiratory: A decline of 5% (3% at CER), reflecting US pricing pressure for Symbicort
- New Oncology: Strong sales with Tagrisso delivering sales of $423 million in its first full year

Our talented employees are committed to achieving our Purpose in a sustainable way and our Values foster a strong AstraZeneca culture

- **59,700** Employees
- **92%** of employees feel able to bring our Values to life in their daily work

Our capital-allocation priorities strike a balance between the interests of the business, our financial creditors and shareholders, and support our progressive dividend policy

<table>
<thead>
<tr>
<th>Distributions to shareholders $m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Dividends</td>
</tr>
<tr>
<td>Proceeds from issue of shares</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dividend per Ordinary Share $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Dividend per Ordinary Share</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dividend per Ordinary Share for 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
</tr>
<tr>
<td>--------------------------------------</td>
</tr>
<tr>
<td>First interim dividend</td>
</tr>
<tr>
<td>Second interim dividend</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>
Dividends and other important information for shareholders

Dividend payment and dates
The record date for the second interim dividend for 2016, payable on 20 March 2017, is 17 February 2017. Shares listed in London and Stockholm traded ex-dividend from 16 February 2017. American Depositary Shares listed in New York traded ex-dividend from 15 February 2017. The record date for the first interim dividend for 2017, payable on 11 September 2017, is 11 August 2017. Future dividends will normally be paid as follows:

First interim: Announced in July/August and paid in September. Second interim: Announced in January/February and paid in March.

Shareview
The Company’s shareholders with internet access may visit the website, www.shareview.co.uk, and register their details to create a portfolio. Shareview is a free and secure online service from the Company’s registrars, Equiniti, which gives access to shareholdings, including balance movements, indicative share prices and information about recent dividends.

ShareGift
The Company welcomes and values all of its shareholders, no matter how many or how few shares they own. However, shareholders who have only a small number of shares whose value makes it uneconomic to sell them, either now or at some stage in the future, may wish to consider donating them to charity through ShareGift, an independent charity share donation scheme. One feature of the scheme is that there is no gain or loss for UK capital gains tax purposes on gifts of shares through ShareGift, and it may now also be possible to obtain UK income tax relief on the donation. Further information about ShareGift can be found on its website, www.sharegift.org, or by contacting ShareGift on 020 7930 3737 or at 17 Carlton House Terrace, London SW1Y 5AH. ShareGift is administered by The Orr Mackintosh Foundation, registered charity number 1052686. More information about the UK tax position on gifts of shares to ShareGift can be obtained from HM Revenue & Customs on their website, www.hmrc.gov.uk.

The Unclaimed Assets Register
The Company supplies unclaimed dividend data to the Unclaimed Assets Register (UAR), which provides investors who have lost track of shareholdings with an opportunity to search the UAR’s database of unclaimed financial assets on payment of a small fixed fee. The UAR donates part of the search fee to charity. The UAR can be contacted on 0870 241 1713 or at PO Box 9501, Nottingham NG80 1WD.

Results
Unaudited trading results of AstraZeneca in respect of the first three months of 2017 will be published on 27 April 2017 and results in respect of the first six months of 2017 will be published on 27 July 2017.

Our website
This letter is also available on our website, www.astrazeneca.com/shareholderletter2016.

Registered office
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
UK
Tel: +44 (0)20 3749 5000

Investor relations
UK: as above

US:
Investor Relations
AstraZeneca Pharmaceuticals LP
One MedImmune Way
Gaithersburg MD 20878
US
Tel: +1 (301) 398 0000

Registrar
Equiniti
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA
UK
Tel: (freephone in the UK)
0800 389 1580
Tel: (outside the UK)
+44 (0)121 415 7033

US Depositary
Citibank Shareholder Services
PO Box 43077
Providence
RI 02940-3077
US
Tel: (toll free in the US)
+1 888 697 8018
Tel: (outside the US)
+1 781 575 4555
citibank@shareholders-online.com

Swedish Central Securities Depository
Euroclear Sweden AB
PO Box 191
SE-101 23 Stockholm
Sweden
Tel: +46 (0)8 402 9000